1. Share Prices

  2. Ondine Biomedical Inc. (OBI)

8.25p+0.13 (+1.54%)22 Nov 2024, 16:35
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Ondine Biomedical Inc. Fundamentals

Company NameOndine Biomedical Inc.Last Updated2024-11-22
IndustryBiotechnologySectorHealthcare
Shares in Issue300.458 mMarket Cap£24.79 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-0.07 CADEPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0872Debt Equity Ratio0
Asset Equity Ratio211.8421Cash Equity Ratio64.1053
Quick Ratio0.3635Current Ratio0.80
Price To Book Value2,500.0000ROCE0

Ondine Biomedical Inc. Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Ondine Biomedical Inc. Company Financials

Assets202320222021
Tangible Assets949,000.00 CAD1.40 m CAD601,000.00 CAD
Intangible Assets000
Investments000
Total Fixed Assets984,000.00 CAD1.44 m CAD636,000.00 CAD
Stocks1.07 m CAD1.29 m CAD1.06 m CAD
Debtors326,000.00 CAD182,000.00 CAD248,000.00 CAD
Cash & Equivalents2.98 m CAD13.13 m CAD30.36 m CAD
Other Assets000
Total Assets5.73 m CAD16.57 m CAD34.14 m CAD
Liabilities202320222021
Creditors within 1 year3.49 m CAD3.91 m CAD3.92 m CAD
Creditors after 1 year159,000.00 CAD1.02 m CAD561,000.00 CAD
Other Liabilities000
Total Liabilities3.65 m CAD4.92 m CAD4.48 m CAD
Net assets2.08 m CAD11.64 m CAD29.66 m CAD
Equity202320222021
Called up share capital239.65 m CAD235.04 m CAD235.04 m CAD
Share Premium000
Profit / Loss-14.41 m CAD-19.37 m CAD-50.09 m CAD
Other Equity2.08 m CAD11.64 m CAD29.66 m CAD
Preference & Minorities000
Total Capital Employed2.08 m CAD11.64 m CAD29.66 m CAD
Ratios202320222021
Debt Ratio0.07 CAD0.04 CAD0.00 CAD
Debt-to-Equity0.08 CAD0.05 CAD0.00 CAD
Assets / Equity211.8421211.8421211.8421
Cash / Equity64.105364.105364.1053
EPS-0.07 CAD-0.09 CAD-0.23 CAD
Cash Flow202320222021
Cash from operating activities-13.65 m CAD-16.34 m CAD-12.54 m CAD
Cashflow before financing-9.87 m CAD-16.62 m CAD29.36 m CAD
Increase in Cash-10.04 m CAD-16.93 m CAD29.29 m CAD
Income202320222021
Turnover1.20 m CAD638,000.00 CAD2.57 m CAD
Cost of sales500,000.00 CAD351,000.00 CAD1.31 m CAD
Gross Profit703,000.00 CAD287,000.00 CAD1.25 m CAD
Operating Profit-14.80 m CAD-18.76 m CAD-17.52 m CAD
Pre-Tax profit-14.41 m CAD-19.37 m CAD-50.09 m CAD

Ondine Biomedical Inc. Company Background

SectorHealthcare
ActivitiesOndine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportableoperating segment that is antimicrobial photodynamic therapy (aPDT) products.
Latest Interim Date30 Sep 2024
Latest Fiscal Year End Date7 Jun 2024

Ondine Biomedical Inc. Directors

AppointedNamePosition
2024-05-03Mr. Craig A. ToomanNon-Executive Director
2024-11-22Ms. Carolyn CrossExecutive Director,Chief Executive Officer
2011-09-06Mr. Colin D. WattExecutive Director
2024-11-22Dr. Nicholas LoebelPresident and Chief Technology Officer
2011-09-06Mr. Michael CraneExecutive Director
2011-09-06Mr. Terry M. HollandExecutive Director
2024-11-22Ms. Margaret ShawNon-Executive Director
2010-12-21Dr. Merrill BielExecutive Director
2011-08-09Mr. Pierre LeducExecutive Director,Chairman
2024-11-22Dr. Junaid BajwaNon-Executive Director
2024-11-22Mr. Jean CharestNon-Executive Director,Chairman
2024-11-22Ms. Jean DuvallNon-Executive Director,Senior Independent Non-Executive Director
2024-11-22Mr. Michael FarrarNon-Executive Director
2024-06-27Dr. Simon SinclairNon-Executive Director

Ondine Biomedical Inc. Contact Details

Company NameOndine Biomedical Inc
Address1100 Melville Street, Suite 888, Vancouver, V6E4A6
Telephone+1 604 669-0555
Websitehttps://www.ondinebio.com

Ondine Biomedical Inc. Advisors

AuditorErnst & Young LLP
AuditorErnst & Young Ltd.
AuditorDavidson & Company LLP
Phone+1 604 687-0947

Most Read

Receive our
daily news email

Subscribe to the latest investing news by entering your email address below

You can opt out at any time.

For five days a week you will get

  • The latest company news
  • Insight into investment trends
  • Round-up of director's buys and sells
  • Articles from Shares magazine
Sharesmagazine cover

Plus more useful investment content and occasional promotional offers.

Shares Magazine Latest Issue Cover
Latest Issue:
21 Nov 2024Subscribe now

Market Overview

UK 350 Risers and Fallers

(No risers / fallers data found)